|
|
 |
 |
| |
 Printable version |
Inhaled magnesium sulphate in the treatment of bronchial hyperresponsiveness |
Magnesium Research. Volume 25, Number 4, 168-76, December 2012, Original article
|
 Full Text
|
Author(s) : Fedoua Gandia, Hervé Guénard, Badreddine Sriha, Zouhair Tabka, Sonia Rouatbi |
Summary : Magnesium sulphate (MgSO
4) is one of numerous treatment options available during acute asthma exacerbation. A significant, bronchodilating effect of intravenous MgSO
4 has been demonstrated in previous studies, but its inhaled use is less well-defined.
Objective: To investigate the effects of inhaled MgSO
4 alone and in association with a
β
2-agonist in the treatment of bronchial hyperresponsiveness.
Methods. We conducted a placebo-controlled, double-blind clinical trial with seventy six adult patients with bronchial hyperresponsiveness. Subjects were randomized into four groups receiving four inhaled products at the end of methacholine (Mech) challenge: NaCl 0.9%, MgSO
4 alone,
β
2-agonist alone, and the combination of MgSO
4 +
β
2-agonist. Repeated measures of the forced expiratory volume at 1s (FEV
1) were performed at 0, 5, 10, and 20 minutes after the end of the inhalations. In the MgSO
4 and MgSO
4 +
β
2-agonist groups, a blood sample was taken before and after inhalation to determine serum magnesium levels.
Results.
(1) Inhaled MgSO
4 led to a significant improvement of the FEV
1 from the 15
th minute after its inhalation. (
2)
β
2-agonist significantly increased FEV
1 from the 5
th minute
(3) inhaled MgSO
4 +
β
2-agonist led to a significantly greater FEV
1 from the 5
th minute than inhaled MgSO
4 alone or inhaled
β
2-agonist alone
(p<\;0.05)
(4) There is a correlation between low serum magnesium level and the increase in FEV
1 after inhalation of MgSO
4 +
β
2-agonist (p<\;0.001).
Conclusion Inhaled MgSO
4,
in combination with
β
2-agonist, appears to have benefits in the treatment of bronchial hyperresponsiveness, especially when associated with hypomagnesemia. |
Keywords : inhaled magnesium sulphate,
β
2-agonist, asthma, FEV
1 |
|
